Gilead CEO Daniel O’Day told STAT he’s confident in the company’s pricing decision for the COVID-19 drug remdesivir.
“We spent a lot of time and considerable care and discussion about how to approach the pricing of this medicine,” he said. “At this price it’s significantly below the value it brings to patients and to society. There is no doubt of that in my mind.”
The drug will cost governments of developed nations $2,340 for a full five-day course, whereas insurers will be charged $3,120.
Peter Bach, director of the Center for Health Policy and Outcomes at Memorial Sloan Kettering Cancer Center, called Gilead’s pricing decision “entirely predictable.”
“They take the highest number anybody has floated, they cut down a bit from there, and they say now they’re the good guys,” he told STAT.
To read the full report on STAT, click here.
